Sequential Use of Low-dose Sunitinib With Chemotherapy in Advanced NSCLC After Failure of Conventional Regimen
NCT01850147
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
50
Enrollment
OTHER
Sponsor class
Conditions
Cancer
Lung Cancer
Interventions
DRUG:
Sunitinib, chemotherapy
Sponsor
Chinese Academy of Medical Sciences